Clinical Trial Update: A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Pegasys (peginterferon alfa-2a) to untreated control in children with HBeAg-positive chronic hepatitis B; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis B, Chronic | Phase 3 | Status: COMPLETED | Results posted: 2016-08-17